company:eli-lilly
Eli Lilly brands GLP1s as "anti-hedonics"
Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"
company:eli-lilly
category:news
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
category:news
Compounders sue FDA over Tirzepatide shortage changes
Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
category:news
Why the Tirzepatide shortage ending might be bad news.
Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.
company:eli-lilly
Eli Lilly's other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.
company:eli-lilly
Eli Lilly China approval and new suppliers
As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.